LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 46

Search options

  1. Article ; Online: The authors reply.

    Teoh, Jeremy Yuen-Chun / Chan, Vinson Wai-Shun

    Critical care medicine

    2021  Volume 49, Issue 10, Page(s) e1056–e1057

    Language English
    Publishing date 2021-09-16
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 197890-1
    ISSN 1530-0293 ; 0090-3493
    ISSN (online) 1530-0293
    ISSN 0090-3493
    DOI 10.1097/CCM.0000000000005235
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The FIX-IT study: authors' response to a letter to the editor.

    Asif, Aqua / Warren, Hannah / Clement, Keiran D / Light, Alexander / Chan, Vinson Wai-Shun / Khadhouri, Sinan / Shah, Taimur T / Kasivisvanathan, Veeru

    BJU international

    2023  Volume 131, Issue 4, Page(s) 514–515

    Language English
    Publishing date 2023-02-09
    Publishing country England
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 1462191-5
    ISSN 1464-410X ; 1464-4096 ; 1358-8672
    ISSN (online) 1464-410X
    ISSN 1464-4096 ; 1358-8672
    DOI 10.1111/bju.15976
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Choosing appropriate patient-reported outcome measures for prostate disease.

    Ng, Alexander / Khetrapal, Pramit / Brew-Graves, Chris / Muirhead, Nicola / Asif, Aqua / Chan, Vinson Wai-Shun / Nathan, Arjun / Kasivisvanathan, Veeru

    BJUI compass

    2022  Volume 3, Issue 4, Page(s) 263–266

    Language English
    Publishing date 2022-01-12
    Publishing country United States
    Document type Journal Article
    ISSN 2688-4526
    ISSN (online) 2688-4526
    DOI 10.1002/bco2.136
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Decision Regret in Patients with Localised Prostate Cancer: A Systematic Review and Meta-analysis.

    Fanshawe, Jack B / Wai-Shun Chan, Vinson / Asif, Aqua / Ng, Alexander / Van Hemelrijck, Mieke / Cathcart, Paul / Challacombe, Ben / Brown, Christian / Popert, Rick / Elhage, Oussama / Ahmed, Kamran / Brunckhorst, Oliver / Dasgupta, Prokar

    European urology oncology

    2023  Volume 6, Issue 5, Page(s) 456–466

    Abstract: Context: Treatment choice for localised prostate cancer remains a significant challenge for patients and clinicians, with uncertainty over decisions potentially leading to conflict and regret. There is a need to further understand the prevalence and ... ...

    Abstract Context: Treatment choice for localised prostate cancer remains a significant challenge for patients and clinicians, with uncertainty over decisions potentially leading to conflict and regret. There is a need to further understand the prevalence and prognostic factors of decision regret to improve patient quality of life.
    Objective: To generate the best estimates for the prevalence of significant decision regret localised prostate cancer patients, and to investigate prognostic patient, oncological, and treatment factors associated with regret.
    Evidence acquisition: We performed a systematic search of MEDLINE, Embase, and PsychINFO databases including studies evaluating the prevalence or patient, treatment, or oncological prognostic factors in localised prostate cancer patients. A pooled prevalence of significant regret was calculated with the formal prognostic factor evaluation conducted per factor identified.
    Evidence synthesis: Significant decision regret was present in a pooled 20% (95% confidence interval 16-23) of patients across 14 studies and 17883 patients. This was lower in active surveillance (13%), with little difference between those who underwent radiotherapy (19%) and those who underwent prostatectomy (18%). Evaluation of individual prognostic factors demonstrated higher regret in those with poorer post-treatment bowel, sexual, and urinary function; decreased involvement in the decision-making process; and Black ethnicity. However, evidence remains conflicting, with low or moderate certainty of findings.
    Conclusions: A significant proportion of men experience decision regret after a localised prostate cancer diagnosis. Monitoring those with increased functional symptoms and improving patient involvement in the decision-making process through education and decision aids may reduce regret.
    Patient summary: We looked at how common regret in treatment decisions is after treatment for early-stage prostate cancer and factors linked with this. We found that one in five regret their decision, with those who had experienced side effects or were less involved in the decision-making process more likely to have regret. By addressing these, clinicians could reduce regret and improve quality of life.
    Language English
    Publishing date 2023-03-03
    Publishing country Netherlands
    Document type Journal Article ; Review
    ISSN 2588-9311
    ISSN (online) 2588-9311
    DOI 10.1016/j.euo.2023.02.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Comparison of add-on medications for persistent storage symptoms after α-blocker treatment in BPH patients - a network meta-analysis.

    Su, Yi-Ting / Chen, Hsiao-Ling / Teoh, Jeremy Yuen-Chun / Chan, Vinson Wai-Shun / Wu, Wen-Jeng / Lee, Hsiang-Ying

    BMC urology

    2023  Volume 23, Issue 1, Page(s) 154

    Abstract: Background: Patients with benign prostatic hyperplasia (BPH) receive α-blockers as first-line therapy to treat lower urinary tract symptoms; however, some individuals still experience residual storage symptoms. Antimuscarinics, β3-agonists, and ... ...

    Abstract Background: Patients with benign prostatic hyperplasia (BPH) receive α-blockers as first-line therapy to treat lower urinary tract symptoms; however, some individuals still experience residual storage symptoms. Antimuscarinics, β3-agonists, and desmopressin are effective add-on medications. Nevertheless, there is currently no evidence for the appropriate choice of the first add-on medication. This systematic review aimed to investigate the clinical benefits of antimuscarinics, β3-agonists, and desmopressin, in addition to α-blockers, for persistent storage symptoms in BPH patients.
    Methods: A comprehensive literature search of randomized controlled trials (RCTs) comparing the efficacy of different add-on medications in BPH patients with persistent storage symptoms despite α-blocker treatment was conducted. Clinical outcomes included the International Prostate Symptom Score (IPSS), IPSS storage subscore, nocturia, micturition, and urgency. A network meta-analysis was performed to estimate the effect size. Surface under cumulative ranking curves (SUCRAs) were used to rank the included treatments for each outcome.
    Results: A total of 15 RCTs were identified. Add-on imidafenacin and mirabegron resulted in significant improvement in all outcomes assessed. Other add-on medications such as desmopressin, tolterodine, solifenacin, fesoterodine, and propiverine showed positive benefits for most, but not all, outcomes. Based on the SUCRA rankings, add-on desmopressin was the best-ranked treatment for IPSS and nocturia, and add-on imidafenacin was the best for the IPSS storage subscore and micturition.
    Conclusions: BPH patients presenting with persistent storage symptoms despite α-blocker administration are recommended to include additional treatment. Desmopressin and imidafenacin may be considered high-priority add-on treatments because of their superior efficacy compared with other medications.
    MeSH term(s) Male ; Humans ; Muscarinic Antagonists/therapeutic use ; Prostatic Hyperplasia/complications ; Prostatic Hyperplasia/drug therapy ; Nocturia ; Network Meta-Analysis ; Deamino Arginine Vasopressin/therapeutic use ; Treatment Outcome ; Drug Therapy, Combination ; Lower Urinary Tract Symptoms/drug therapy ; Lower Urinary Tract Symptoms/etiology ; Adrenergic alpha-Antagonists/therapeutic use
    Chemical Substances Muscarinic Antagonists ; Deamino Arginine Vasopressin (ENR1LLB0FP) ; Adrenergic alpha-Antagonists
    Language English
    Publishing date 2023-10-03
    Publishing country England
    Document type Systematic Review ; Meta-Analysis ; Journal Article
    ZDB-ID 2059857-9
    ISSN 1471-2490 ; 1471-2490
    ISSN (online) 1471-2490
    ISSN 1471-2490
    DOI 10.1186/s12894-023-01327-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Finding consensus for orchIdopeXy In Torsion (FIX-IT).

    Clement, Keiran D / Light, Alexander / Asif, Aqua / Wai-Shun Chan, Vinson / Shah, Taimur T / Kasivisvanathan, Veeru

    BJU international

    2020  Volume 126, Issue 5, Page(s) 642–643

    MeSH term(s) Consensus ; Humans ; Male ; Orchiopexy/standards ; Practice Guidelines as Topic ; Spermatic Cord Torsion/surgery ; Surgeons ; Testis/surgery ; United Kingdom
    Language English
    Publishing date 2020-07-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 1462191-5
    ISSN 1464-410X ; 1464-4096 ; 1358-8672
    ISSN (online) 1464-410X
    ISSN 1464-4096 ; 1358-8672
    DOI 10.1111/bju.15271
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Urology teaching in UK medical schools: does it prepare doctors adequately?

    Ng, Alexander / Light, Alexander / Chan, Vinson Wai-Shun / Asif, Aqua / Bhatt, Nikita R / Kasivisvanathan, Veeru

    Nature reviews. Urology

    2020  Volume 17, Issue 12, Page(s) 651–652

    MeSH term(s) Clinical Competence ; Curriculum/standards ; Education, Medical, Undergraduate/standards ; Humans ; United Kingdom ; Urology/education
    Language English
    Publishing date 2020-10-22
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2493737-X
    ISSN 1759-4820 ; 1759-4812
    ISSN (online) 1759-4820
    ISSN 1759-4812
    DOI 10.1038/s41585-020-00393-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Oncological and Peri-Operative Outcomes of Percutaneous Cryoablation of Renal Cell Carcinoma for Patients with Hereditary RCC Diseases-An Analysis of European Multi-Centre Prospective EuRECA Registry.

    Osman, Filzah Hanis / Chan, Vinson Wai-Shun / Breen, David J / King, Alexander / Nielsen, Tommy Kjærgaard / Garnon, Julien / Alcorn, Des / Lagerveld, Brunolf / Graumann, Ole / Keeley, Francis Xavier / Walkden, Miles / de Kerviler, Éric / Wah, Tze Min

    Cancers

    2023  Volume 15, Issue 13

    Abstract: This study aims to evaluate the safety, efficacy, and renal function preservation of percutaneous cryoablation (PCA) for small renal masses (SRMs) in inherited RCC syndromes. Patients with inherited T1N0M0 RCCs (<7 cm) undergoing PCA from 2015 to 2021 ... ...

    Abstract This study aims to evaluate the safety, efficacy, and renal function preservation of percutaneous cryoablation (PCA) for small renal masses (SRMs) in inherited RCC syndromes. Patients with inherited T1N0M0 RCCs (<7 cm) undergoing PCA from 2015 to 2021 were identified from the European Registry for Renal Cryoablation (EuRECA). The primary outcome was local recurrence-free survival (LRFS). The secondary outcomes included technical success, peri-operative outcomes, and other oncological outcomes estimated using the Kaplan-Meier method. Simple proportions, chi-squared tests, and
    Language English
    Publishing date 2023-06-24
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15133322
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Implications and effects of COVID-19 on diagnosis and management of prostate cancer.

    Chan, Vinson Wai-Shun / Asif, Aqua / Koe, Jasmine Sze-Ern / Ng, Alexander / Ng, Chi Fai / Teoh, Jeremy Yuen-Chun

    Current opinion in urology

    2022  Volume 32, Issue 3, Page(s) 311–317

    Abstract: Purpose of review: The Coronavirus disease 2019 (COVID-19) pandemic has led to uncertainty on the optimal management for prostate cancer (PCa). This narrative review aims to shed light on the optimal diagnosis and management of patients with or ... ...

    Abstract Purpose of review: The Coronavirus disease 2019 (COVID-19) pandemic has led to uncertainty on the optimal management for prostate cancer (PCa). This narrative review aims to shed light on the optimal diagnosis and management of patients with or suspected to have PCa.
    Recent findings: Faecal-oral or aerosol transmission is possible during prostate procedures; caution must be in place when performing digital rectal examinations, transrectal ultrasound-guided prostate biopsies and prostate surgeries requiring general anaesthesia. Patients must also be triaged using preoperative polymerase chain reaction tests for COVID-19. COVID-19 has accelerated the adoption of multiparametric Magnetic Resonance Imaging (MRI), reducing the need for prostate biopsy unless when absolutely indicated, and the risk of COVID-19 spread can be reduced. Combined with prostate-specific antigen (PSA) density, amongst other factors, multiparametric MRI could reduce unnecessary biopsies in patients with little chance of clinically significant PCa. Treatment of PCa should be stratified by the risk level and preferences of the patient. COVID-19 has accelerated the development of telemedicine and clinicians should utilise safe and effective teleconsultations to protect themselves and their patients.
    Summary: COVID-19 transmission during prostate procedures is possible. Patients with a Prostate Imaging-Reporting and Data System (PI-RADS) of <3 and PSA density <0.15 ng/ml/ml are deemed low-risk and are safe to undergo surveillance without MRI-targeted biopsy. Intermediate- or high-risk patients should be offered definitive treatment within four months or 30days of diagnosis to avoid compromising treatment outcomes; three-month courses of neoadjuvant androgen deprivation therapy can be considered when a delay of surgery is anticipated.
    MeSH term(s) Androgen Antagonists ; COVID-19 ; Humans ; Image-Guided Biopsy/methods ; Magnetic Resonance Imaging/methods ; Male ; Prostate-Specific Antigen ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/therapy ; Retrospective Studies
    Chemical Substances Androgen Antagonists ; Prostate-Specific Antigen (EC 3.4.21.77)
    Language English
    Publishing date 2022-02-09
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1091792-5
    ISSN 1473-6586 ; 0963-0643
    ISSN (online) 1473-6586
    ISSN 0963-0643
    DOI 10.1097/MOU.0000000000000973
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Lymph node dissection for upper tract urothelial carcinoma: A systematic review.

    Chan, Vinson Wai-Shun / Wong, Chris Ho Ming / Yuan, Yuhong / Teoh, Jeremy Yuen-Chun

    Arab journal of urology

    2020  Volume 19, Issue 1, Page(s) 37–45

    Abstract: Objective: To perform a systematic review, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, investigating the role of lymph node dissection (LND) during nephroureterectomy (NU) for upper tract ... ...

    Abstract Objective: To perform a systematic review, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, investigating the role of lymph node dissection (LND) during nephroureterectomy (NU) for upper tract urothelial carcinoma (UTUC); focussing on survival and complication outcomes.
    Methods: A comprehensive systematic search was completed using a combination of Medical Subject Headings terms and keywords related to UTUC and LND on multiple databases. Meta-analyses were performed when outcomes were reported under the same definition in two or more studies. Where meta-analysis was not possible, outcomes were reviewed in a narrative manner.
    Results: A total of 21 studies were included in the qualitative analysis and 11 cohort studies in the quantitative analysis. Our review did not detect significant improvement in recurrence-free survival (RFS) (hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.41-1.92), cancer-specific survival (CSS) (HR 0.89, 95% CI 0.54-1.46) and overall survival (OS) (HR 1.10, 95% CI 0.93-1.30). However, when focussing on studies only including patients with pT2/pT3 UTUC, not performing LND significantly worsened RFS (HR 2.83, 95% CI 1.72-4.66). Reports of removing more than eight lymph nodes may also provide prognostic benefits in pN0 patients. The performance of LND was not associated with a higher rate of postoperative complications (risk ratio 1.06, 95% CI 1.00-1.13).
    Conclusion: Overall, LND did not provide additional benefit in RFS, CSS and OS. However, there was a potential benefit in RFS in patients with muscle-invasive and advanced UTUC. LND was also not associated with increased risks of postoperative complications.
    Language English
    Publishing date 2020-07-27
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2631788-6
    ISSN 2090-598X
    ISSN 2090-598X
    DOI 10.1080/2090598X.2020.1791563
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top